Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Verily, Alphabet's life sciences arm, has beefed up its advisory board and leadership team as it looks to move beyond research and development and into hospitals and clinics.
The company recently hired Ashraf Hanna, the former CEO of Oric Pharmaceuticals, as its chief operating officer, and brought on Vivian Lee, a radiologist and the former CEO of University of Utah Health, as president of health platforms.
Lee, who left the Utah health system over a controversy related to her firing of an executive, will focus on population health initiatives, furthering the company's interest in managing patient populations.
Verily is starting to more aggressively commercialize its range of services and products, many of which have been in development for more than five years. The company is looking to sell both to pharmaceutical companies and health systems, and is also working with regulators to secure approvals for its products.
"This is not a company with a lack of ambition," said Robert Califf, a former commissioner for the U.S. Food and Drug Administration, who joined the company as an adviser last May. "In health care, there's a lot to be done."
Some of Verily's initiatives, like its device to measure blood using a type of watch, are still in the research phase. But others are further along. In 2016, Verily partnered with Sanofi on a joint venture called Onduo, which is focused on diabetes management.
Verily has also beefed up its scientific advisory board, adding Linda Avey, the co-founder of 23andMe, as well as former Medicare chief Andy Slavitt, former national coordinator for Health Information Technology Karen DeSalvo, and Kathy Giusti, founder of the Multiple Myeloma Research Foundation.
"In the early days, we were very science-oriented so our advisory board spent much of their time reviewing science projects," said Califf. "But now, where we're headed is to delivery, the pragmatic real-world stuff, and we needed a different kind of board."
Both Slavitt and DeSalvo said they are specifically interested in helping Americans with significant medical and social challenges, and not just the healthy and wealthy.
"Technology brings great opportunity to reach hard to reach populations, such as those in rural America," DeSalvo said. It can help "close the disparity gaps."